You are here
Dr Eileen Dunne
Dr Eileen Dunne completed a PhD in microbiology from the Boston University School of Medicine in 2010. Her thesis research involved investigating the mechanisms of action of a synthetic antimicrobial peptide on Gram-positive bacteria. Prior to graduate school, she spent two years in Nicaragua as a member of the Peace Corps and worked at the Harvard School of Public Health. She joined the Pneumococcal Research group at Murdoch Childrens as a postdoctoral scientist in 2010, aiming to apply her background as a molecular microbiologist to research with a focus on international child health.
Dr Dunne became a Senior Research Officer in 2012 and is currently involved in several international collaborations supporting the use of pneumococcal vaccines in resource-limited settings. She is a co-investigator on grants totalling over $11 million from funders including GAVI and the Bill and Melinda Gates Foundation.
- Robert Austrian Award in Pneumococcal Vaccinology, prestigious young investigator award, 2014
- Travel Grant, 8th International Symposium on Pneumococci and Pneumococcal Diseases, 2012
- Morgan Stanley Pediatrics Fellowship, American Australian Association, 2010
- Millis-Colwell Travel Grant for Early Career Scientists, American Society of Microbiology, 2010
Dr Dunne's research focuses on Streptococcus pneumoniae and other respiratory pathogens in children. Key interests include evaluating the effects of pneumococcal vaccination on bacterial carriage and the development and implementation of surveillance methods for molecular epidemiology of bacteria. She is involved in pneumococcal conjugate vaccine (PCV) impact studies in Fiji, Lao PDR, and Mongolia, a PCV trial in Vietnam, and is leading a pneumococcal carriage study ahead of a planned pneumococcal whole cell vaccine trial in Indonesia. Dr Dunne is also helping to establish new pneumococcal serotyping methods at Murdoch Childrens, and uses experimental models to further understand the pneumococcal disease process and investigate immunisation and potential strategies to combat this important pathogen.
Dr Dunne enjoys fieldwork and supporting the use of molecular microbiology in-country with international collaborators, as well as working with the laboratory-based research team at the Murdoch Childrens to answer interesting microbiological questions with clinical impact.
1. Vaccine impact studies in Fiji and Lao PDR
- New Vaccine Evaluation Project, Fiji
- Evaluation of the impact of national pneumococcal conjugate vaccine introduction in Lao PDR
2. Whole-cell vaccine program
- Indonesian Pneumococcal Project – Pneumococcal carriage in Indonesian infants ahead of the Streptococcus pneumonia whole cell vaccine efficacy trial
- Impact of pneumococcal whole-cell vaccine on otitis media and transmission in vivo
3. Serotype Replacement Study
- PneuCarriage follow-up study “monitoring pneumococcal carriage and vaccine impact'
4. Centre of Research Excellence in Pneumococcal Vaccinology.
5. Pneumococcal gene expression – impact of environmental factors, and identifying the differences between carriage and disease states.
Licciardi PV, Toh ZQ, Clutterbuck EA, Balloch A, Marimla RA, Tikkanen L, Lamb KE, Bright KJ, Rabuatoka U, Tikoduadua L, Boelsen L, Dunne EM, Satzke C, Cheung YB, Pollard AJ, Russell FM, and Mulholland EK. No long-term evidence of hyporesponsiveness following pneumococcal polysaccharide booster at 12-months of age. J Allergy Clin Immunol. 2016 Jun;137(6):1772-1779.e11.
Satzke C, Dunne EM, Porter BD, Klugman KP, Mulholland EK; PneuCarriage project group. The PneuCarriage Project: A multi-centre comparative study to identify the best serotyping methods for examining pneumococcal carriage in vaccine evaluation studies. PLoS Med. 2015 Nov 17;12(11):e1001903.
Boelsen LK, Dunne EM, Bright K, Lamb KE, Cheung YB, Tikoduadua L, Russell FM, Mulholland EK, Licciardi PV, and Satzke C. Long-term impact of pneumococcal polysaccharide vaccination on nasopharyngeal carriage in children following a reduced dose pneumococcal conjugate vaccine primary series in infancy. Vaccine. 2015 Oct 13;33(42):5708-14.
Dunne EM, Tikkanen L, Balloch A, Gould K, Yoannes M, Phuanukoonnon S, Licciardi P, Russell FM, Mulholland K, Satzke C, and Hinds J. Characterization of 19A-like 19F pneumococcal isolates from Papua New Guinea and Fiji. New Microbes New Infect. 2015: 7:86- 88.
Hoe E, Boelsen LK, Toh ZQ, Sun GW, Koo GC, Balloch A, Marimla R, Dunne EM, Tikoduadua L, Russell FM, Satzke C, Mulholland EK, and Licciardi PV. Reduced IL-17A secretion is associated with high levels of pneumococcal nasopharyngeal carriage in Fijian children. PLoS One. 2015 Jun 12;10(6):e0129199.
Sakai F, Chochua S, Satzke C, Dunne EM, Mulholland K, Klugman KP, Vidal JE. Single-plex quantitative assays for the detection and quantification of most pneumococcal serotypes. PLoS One. 2015 Mar 23;10(3):e0121064.
Dunne EM, Toh ZQ, John M, Manning J, Satzke C, and Licciardi PV. Investigating the effects of probiotics on pneumococcal colonization using an in vitro adherence assay. J Vis Exp. 2014 Apr 28;(86)
Strachan J, Rowe R, Dunne EM, and Hogg G. Emergence of Streptococcus pneumoniae serotype 15A after the introduction of the conjugate vaccine in Victoria, Australia. Med J Aust. 2013. Oct 8;199(7):461-3
Dunne EM, Marshall JM, Baker CA, Manning J, Gonis G, Danchin MH, Smeesters PR, Satzke C, and Steer AC. Detection of group A streptococcal pharyngitis by quantitative PCR. BMC Infect Dis. 2013 Jul 11;13:312
Dunne EM, Smith-Vaughan HC, Robins-Browne RM, Mulholland EK, and Satzke C. Nasopharyngeal microbial interactions in the era of pneumococcal conjugate vaccination. Vaccine. 2013 May 1;31(19):2333-42
John M, Dunne EM, Licciardi PV, Satzke C, Wijburg O, Robins-Browne RM, and O' Leary S. Otitis media among high-risk populations: Can probiotics inhibit Streptococcus pneumoniae colonisation? Eur J Clin Microbiol Infect Dis. 2013 Sep;32(9):1101-10
Dunne EM, Manning J, Russell FM, Robins-Browne RM, Mulholland EK, and Satzke C. Effect of pneumococcal vaccination on nasopharyngeal carriage of S. pneumoniae, H. influenzae, M. catarrhalis, and S. aureus in Fijian children. J Clin Microbiol. 2012 Mar;50(3):1034-8
Binks M, Temple B, Kirkham L-A, Wiertsema SP, Dunne EM, Richmond PC, Marsh R, Leach AJ, and Smith-Vaughan H. Molecular surveillance of true non typeable Haemophilus influenzae : An evaluation of PCR screening assays. PLoS One. 2012;7(3):e34083
Licciardi PV, Toh ZQ, Dunne E, Wong S-S, Mulholland EK, Tang M, Robins-Browne RM, and Satzke C. Protecting against pneumococcal disease: Critical interactions between probiotics and the airway microbiome. PLoS Pathog. 2012 Jun;8(6):e1002652
Dunne EM, Ong EK, Moser RJ, Siba PM, Phuanukoonnon S, Greenhill AR, Robins-Browne RM, Mulholland EK, and Satzke C. Multilocus sequence typing of Streptococcus pneumoniae by use of mass spectrometry. J Clin Microbiol. 2011 Nov;49(11):3756-60
Dunne EM, Montgomery J, Lupiwa T, Michael A, and Lehmann D. Streptococcus pneumoniae serogroups and colony morphology: a look back. PNG Med J Focus issue on Pneumonia Research, Sept-Dec 2010, Vol 53, issue 3-4